Prodromal DEtErminants for PhENoconversion of idiopathic RBD to alpha-synucleinopathies
| Reference number | |
| Coordinator | Lunds universitet - Institutionen för experimentell medicinsk vetenskap |
| Funding from Vinnova | SEK 3 000 000 |
| Project duration | December 2022 - December 2025 |
| Status | Ongoing |
| Venture | European partnership for Personalised Medicine |
| Call | ERA PerMed Joint Transnational Call 2022: Personalised Prevention |
Purpose and goal
The goal of the project is reliable prediction of phenoconversion from idiopathic REM sleep disorder to neurodegenerative diseases and personalized medicine and treatment.
Expected effects and result
Implementation of pathogenicity model to be used to predict disease development in patients. This will have important consequences on diagnosis and treatment of affected individuals.
Planned approach and implementation
We are going to collect patient information together with clinical partners and then define the three constituent parameters of the model. Information from patients will be used for defining in evidence-based way thresholds for the diseases. The model will be used also for prognosis. Pathogenicity model will be tested with patient cases and developed in iterative cycles.